Intra-Cellular Therapies announces positive pre-NDA meeting with FDA for lumateperone
Intra-Cellular Therapies announced the Company had a positive pre-New Drug Application meeting with the FDA regarding lumateperone for treatment of schizophrenia. The Company and FDA agreed on the proposed content and timing of a rolling NDA submission. March 13, 2018